Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome-Reference-Cited by-同舟云学术

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Published:2020-01 Issue:2 Volume:75 Page:133-144
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Bittner Vera A.,Szarek Michael,Aylward Philip E.,Bhatt Deepak L.,Diaz Rafael,Edelberg Jay M.,Fras Zlatko,Goodman Shaun G.,Halvorsen Sigrun,Hanotin Corinne,Harrington Robert A.,Jukema J. Wouter,Loizeau Virginie,Moriarty Patrick M.,Moryusef Angèle,Pordy Robert,Roe Matthew T.,Sinnaeve Peter,Tsimikas Sotirios,Vogel Robert,White Harvey D.,Zahger Doron,Zeiher Andreas M.,Steg Ph. Gabriel,Schwartz Gregory G.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies;Tsimikas;J Am Coll Cardiol,2017

2. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology;Nordestgaard;J Lipid Res,2016

3. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial;Schwartz;JAMA Cardiol,2018

4. Lipoprotein(a) for risk assessment in patients with established coronary artery disease;O'Donoghue;J Am Coll Cardiol,2014

5. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis;Burgess;JAMA Cardiol,2018

Cited by 340 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-09-06

2. Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab;Pharmacological Research;2024-09

3. Testing practices and clinical management of lipoprotein(a) levels: A 5-year retrospective analysis from the Johns Hopkins Hospital;American Journal of Preventive Cardiology;2024-09

4. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond;American Journal of Preventive Cardiology;2024-09

5. Moderate Aortic Stenosis—Advanced Imaging, Risk Assessment, and Treatment Strategies;Structural Heart;2024-09